Date: December 8-11, 2007
Loacation: Atlanta, Georgia
Thrombopoietin Receptor Agonists & Immune Thrombocytopenic Purpura (ITP): A Report from the 2007 American Society of Hematology (ASH) Meeting
Charles S. Abrams, MD, Associate Professor of Medicine, Director, Thrombophilia Program, University of Pennsylvania Health System, Philadelphia, Pennsylvania
Advances in the Management of Chronic Myeloid Leukemia: A Report from the 2007 American Society of Hematology (ASH) Meeting
Hagop M. Kantarjian, MD, Chairman & Professor, Leukemia Department, University of Texas M. D. Anderson Cancer Center, Houston, Texas
Updates in the Management of Myelodysplastic Syndromes: A Report from the 2007 American Society of Hematology (ASH) Meeting
Mikkael A. Sekeres, MD, MS, Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio
Ask the Experts About Circulating Tumor DNA in the Management of Cancer
Ask the Experts About Circulating Tumor DNA (ctDNA) in the Management of Cancer
Tisotumab Vedotin – Promising in Advanced Cervical Cancer
Novel precision cancer medicine promising for treatment of advanced ovarian cancer.
Checkpoint Inhibitor Immunotherapy for Treatment of Advanced Cervical Cancer
Checkpoint inhibitor immunotherapy prolongs survival and delays recurrence in advanced cervical cancer.
Supportive Care and Hematologic Malignancies: Updates from the 2007 American Society of Hematology (ASH) Meeting
C. Dean Buckner, MD, Founding Member, Fred Hutchinson Cancer Research Center
